iRhythm Technologies (NASDAQ:IRTC) Insider Sells $1,056,953.10 in Stock

iRhythm Technologies (NASDAQ:IRTC) insider Patrick Michael Murphy sold 7,805 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total transaction of $1,056,953.10. Following the transaction, the insider owned 60,536 shares in the company, valued at $8,197,785.12. The trade was a 11.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Patrick Michael Murphy also recently made the following trade(s):

• On Tuesday, December 2nd, Patrick Michael Murphy sold 2,478 shares of iRhythm Technologies stock. The stock was sold at an average price of $184.83, for a total transaction of $458,008.74.

iRhythm Technologies Trading Up 3.1%

Shares of IRTC traded up $4.28 during trading hours on Thursday, hitting $140.18. The company had a trading volume of 390,027 shares, compared to its average volume of 725,398. The company has a quick ratio of 4.48, a current ratio of 4.63 and a debt-to-equity ratio of 4.25. The stock’s 50 day moving average price is $162.85 and its 200 day moving average price is $170.94. The firm has a market cap of $4.53 billion, a P/E ratio of -100.13 and a beta of 1.06. iRhythm Technologies has a 52-week low of $92.52 and a 52-week high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings data on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.27. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The firm had revenue of $208.89 million during the quarter, compared to the consensus estimate of $202.61 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The business’s revenue was up 27.1% on a year-over-year basis. On average, research analysts predict that iRhythm Technologies will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IRTC shares. Evercore upgraded shares of iRhythm Technologies from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $194.00 to $210.00 in a report on Monday, January 5th. Wells Fargo & Company lowered their price objective on iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, February 20th. Wall Street Zen upgraded shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. JPMorgan Chase & Co. lowered their price target on iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating on the stock in a report on Friday, February 20th. Finally, Truist Financial restated a “buy” rating and issued a $200.00 target price (down from $215.00) on shares of iRhythm Technologies in a report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $211.62.

Institutional Investors Weigh In On iRhythm Technologies

A number of institutional investors have recently bought and sold shares of IRTC. Root Financial Partners LLC bought a new stake in shares of iRhythm Technologies during the third quarter valued at approximately $30,000. Measured Wealth Private Client Group LLC purchased a new stake in iRhythm Technologies during the 3rd quarter valued at $30,000. GAMMA Investing LLC lifted its holdings in shares of iRhythm Technologies by 48.4% in the 4th quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after acquiring an additional 60 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in iRhythm Technologies by 100.0% in the third quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock worth $34,000 after purchasing an additional 99 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new stake in shares of iRhythm Technologies during the 3rd quarter worth approximately $34,000.

iRhythm Technologies News Roundup

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat expectations — revenue grew ~27% year-over-year and EPS beat consensus (reported $0.29 vs. $0.02 est.), which supports the rally and longer-term growth thesis. MarketBeat IRTC summary
• Positive Sentiment: Large institutional positions and recent additions by firms such as Vanguard, RTW and UBS signal continued investor confidence and provide a stable shareholder base. Institutional holdings details
• Neutral Sentiment: Analyst coverage remains mostly positive overall (consensus “Moderate Buy”), but several firms trimmed targets after results while others left or raised targets — a mixed signal that keeps valuation expectations varied. Analyst note roundup
• Negative Sentiment: CEO Quentin Blackford sold 25,540 shares (~$3.46M at ~$135.42), reducing his stake by ~12% — a large, disclosed insider sale that investors often view negatively when concentrated. SEC filing: CEO Form 4
• Negative Sentiment: Other insiders also sold shares this week (EVP Mervin Smith, CAO Marc Rosenbaum, insider Patrick Murphy and Director Abhijit Talwalkar), further reducing internal ownership and adding selling pressure. Relevant filings: Murphy SEC filing Murphy Form 4; Rosenbaum/Smith filings available via MarketBeat links above.
• Negative Sentiment: Short interest jumped ~20% in February to about 3.4M shares (≈10.6% of float), raising the stock’s short-interest ratio to ~5 days — this increases volatility risk and the potential for downside on negative news. Short interest data

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.